US 12,268,678 B2
Formulations of hydroxypyridonate actinide/lanthanide decorporation agents
Rebecca J. Abergel, Kensington, CA (US); Taylor A. Choi, South San Francisco, CA (US); Kenneth N. Raymond, Berkeley, CA (US); and David K. Shuh, Oakland, CA (US)
Assigned to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
Filed by THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
Filed on Feb. 4, 2022, as Appl. No. 17/665,135.
Application 17/665,135 is a continuation of application No. 16/330,601, granted, now 11,684,614, previously published as PCT/US2017/050121, filed on Sep. 5, 2017.
Claims priority of provisional application 62/384,087, filed on Sep. 6, 2016.
Prior Publication US 2022/0152003 A1, May 19, 2022
Int. Cl. A61K 31/444 (2006.01); A61K 9/00 (2006.01); A61K 9/16 (2006.01); A61K 9/20 (2006.01); A61P 39/04 (2006.01)
CPC A61K 31/444 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0056 (2013.01); A61K 9/0095 (2013.01); A61K 9/1611 (2013.01); A61K 9/1623 (2013.01); A61K 9/1652 (2013.01); A61K 9/2009 (2013.01); A61K 9/2018 (2013.01); A61K 9/2054 (2013.01); A61P 39/04 (2018.01)] 20 Claims
OG exemplary drawing
 
1. A method for treating a subject for a heavy metal exposure, the method comprising:
administering to the subject having an excess amount of heavy metal a therapeutically effective amount of a pharmaceutical composition comprising:
a 1,2-HOPO chelating agent in an amount from about 100 mg to about 1500 mg; and
sodium oleate,
decorporating, clearing, and/or reducing the excess amount of heavy metal from the subject.